Garber Alan J, Spann Stephen J
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA.
J Fam Pract. 2008 Sep;57(9 Suppl):S10-8.
This article reviews many of the key incretin clinical trials, with a focus on the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo and other glucose-lowering agents used as comparators. These agents have been tested either as monotherapy or in combination with one or more oral antidiabetic drugs (OADs). The article also discusses some of the important clinical differences between GLP-1 receptor agonists and DPP-4 inhibitors.
本文回顾了许多关键的肠促胰岛素临床试验，重点关注胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂与安慰剂及用作对照的其他降糖药物相比的疗效和安全性。这些药物已作为单一疗法或与一种或多种口服抗糖尿病药物（OADs）联合进行了测试。本文还讨论了GLP-1受体激动剂和DPP-4抑制剂之间一些重要的临床差异。
